Biofunctional antibodies can either mimic or interrupt the natural biologic effects associated with ligand-receptor interactions, or have a physiological effect on a target cell or molecule. They may be used in several functional assays, including depletion, activation, neutralization, or blocking experiments. BioLegend offers antibodies in multiple formats for in vivo and in vitro assays. We are also committed to provide the highest quality and standards.


Contact our sales team for quotes on custom and bulk orders.

While ELISAs and flow cytometry are useful tools for scientific analysis, in vivo and in vitro functional assays can provide a unique set of answers. For these types of experiments, BioLegend has been providing 0.2 micron sterile-filtered, Low Endotoxin, Azide-Free (LEAF™) and Ultra-Low Endotoxin, Azide-Free (Ultra-LEAF™) antibody formulations, which eliminate unwanted effects from endotoxin and sodium azide. The major difference between these two formulations is the guaranteed endotoxin content. Please contact our technical service group if you have any questions.


leaf v ultraleaf image

Why buy in bulk?

  • Outstanding value.
  • Each lot is quality-tested and backed by our 100% guarantee.
  • Bulk orders provided as Ultra-LEAF™ (<0.01 EU/µg of protein).
  • Rapid turnaround time (typically 2-3 weeks).

Custom Options

  • Bulk production from your hybridoma.
  • Custom concentrations available.
  • Custom endotoxin limits.
  • Custom formulation of purified or fluorophore-conjugated antibody.
  • Flexible packaging.
purity determination image

Each lot of Purified and Ultra-LEAF™ Purified antibody is assessed for purity by SDS-PAGE.

Blockade of PD-L1 increases T cell activation




PD-1 and CD25 expression on CD4+ T cell splenocytes from melanoma bearing C57BL/6 mice 14 days after serial injection (200 µg by I.V. injection on days 0, 3, 6) of GoInVivo™ anti-PD-L1 antibody clone 10F.9G2 (Cat. No. 124328) or Isotype control (Cat. No. 400666)


Ultra-LEAF™ Purified anti–VEGF–121 Antibody 

Recombinant human VEGF-121 (cat. no. 583202) stimulates proliferation of HUVEC in a dose-dependent manner (dark purple squares). Proliferation induced by recombinant human VEGF-121 (15 ng/mL) is neutralized (purple circles) by increasing concentrations of Ultra-LEAF™ anti-human VEGF-121 monoclonal antibody (Clone A15136B). The ND50 is typically 25 – 100 ng/mL.

Ultra–LEAF™ Purified anti–CCL15 Antibody

Recombinant human CCL15 chemoattracts Baf3-hCCR1 transfectants in a dose dependent manner (purple circles). Ultra-LEAF™ anti-human CCL15 antibody (clone A15015A, purple squares) neutralizes the chemoattraction of Baf3-hCCR1 transfectants induced by recombinant human CCL15 (6 ng/ml). The ND50 is typically 0.05 – 0.25 µg/ml.

View papers citing BioLegend’s biofunctional antibodies.

Human CD3

1. Babich, A. et al. 2012. J. Cell Biol. 197:775

2. Qi, Y. et al. 2012. PLoS One. 7:e9072.

3. Sanford, D.E. et al. 2013. Clin. Cancer Res. 19:3404.

Human CD16

1. Van der Heijden, J. et al. 2012. J. Immunol. 188:1318.

Human CD18

1. Valenzuela, N.M. et al. 2013. J. Immunol. 190:6635.

Human CD28

1. Newell, E. W. et al. 2012. Immunity. 36:142.

Human CD40

1. Iwata, Y. et al. 2011. Blood. 117:530.

Human CD42b

1. Meyer dos Santos, S. et al. 2011. Blood. 117:4999.

Human CD49d

1. Mattapallil, M.J. et al. 2011. J. Immunol. 187:1977.

Human CD206 (MMR)

1. Sorvillo, N. et al. 2012. Blood. 119:3828.

Human CD282 (TLR2)

1. Ching-Liang, C. et al. 2012. PLoS One. 7:e40873.

Human CD352 (NTB-A)

1. Uzana, R. et al. 2012. J. Immunol. 188:632.

Human HLA-A, B, C

1. Chan, W.K. et al. 2012. Clin. Cancer Res. 18:6296.

2. Everds, N. et al. 2013. ToxicolPathol. [epub ahead of print]

Human HLA-DR

1. Dillon, S.M. et al. 2012. J. Immunol. 189:885.

Human IL-2

1. Okano, S. et al. 2011. J. Immunol. 186:1828.

Human Tim-3

1. Elahi, S. et al. 2012. Blood. 119:4192.

2. Moorman, J.P. et al. 2012. J. Immnol. 189:755.

3. Wang, J.M. et al. 2013. J. Virol. 87:4372.

Mouse CD3ε

1. Ashkenazi, A. et al. 2013. Blood. 121:2244.

2. Cheng-Chi, W. et al. 2012. Cell Immunol. 273:30.

Mouse CD16/32

1. Housley, W.J. et al. 2011. J. Immunol. 187:4161.

2. Lochhead, R.B. et al. 2012. J. Immunol. 189:2488.

3. Parra, D. et al. 2012. J. LeukocBiol. 91:525.

Mouse CD25

1. Tewalt, E.F. et al. 2012. Blood. 120:4772.

Mouse CD28

1. Myers, R.C. et al. 2013. J. Immunol. 190:6287.

2. Rybakin, V. et al. 2012. PLoS One. 7:e43191.

Mouse CD47

1. Azcutia, V. et al. 2012. J. Immunol. 189:2553.

Mouse CD54

1. Lask, A. et al. 2013. Blood. 121:3033.

Mouse CD115 (CSF-1R)

1. Gόmez-Nicola, D. et al. 2013. J. Neurosci. 33:2481.

Mouse CD134 (OX-40)

1. Takanori, S. et al. 2011. J. Immunol. 186:3547.

Mouse CD178 (FasL)

1. Nakahira, M. and Nakanishi, K. 2011. Int. Immunol. 23:761.

Mouse CD274

1. Muthumani, K. et al. 2011. J. Immunol. 187:2932.

Mouse IFN-β

1. Zaric, S.S. et al. 2011. J. Biol. Chem. 286:29492.

Mouse IFN-γ

1. Krishnaswamy, J.K. et al. 2012. Am. J. Respir. Cell Mol. Biol. 47:852.

Mouse IL-2

1. Sitrin, J. et al. 2013. J. Exp. Med. 190:5037.

Mouse IL-10

1. Guo, Z. et al. 2013. J. Immunol. 190:4337.

Mouse IL-17A

1. Guo, X. et al. 2011. Vaccine. 29:772.

Mouse LAP (TGF-β1)

1. Zhidan, T. et al. 2012. Invest. Opthalmol. Vis. Sci. 53:959.

Mouse TLR4 (CD284)/MD2 Complex

1. Yonggang, M. et al. 2012. PLoS One. 7:e40763.

Mouse TNF-α

1. Gόmez-Hernández, A. et al. 2013. Endocrinology. 154:2352.

2. Gόmez-Hernández, A. et al. 2012. Endocrinology. 153:1242.

Mouse VEGF-A

1. Lu, R. et al. 2012. Cancer Res. 72:2239.


Login / Register
Remember me
Forgot your password? Reset password?
Create an Account